The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action. by Stratford, I. J. et al.
Br. J. Cancer (1986) 53, 339-344
The differential cytotoxicity of RSU 1069: Cell survival
studies indicating interaction with DNA as a possible mode
of action
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Summary The hypoxic cell radiosensitizer RSU 1069 (1-(2-nitro-1-imidazolyl)-3-(1-aziridinyl)-2-propanol)
shows, on a concentration basis, a 100-fold greater toxicity towards hypoxic relative to aerobic cells. This
toxicity is substantially greater than that of misonidazole, a compound of similar electron affinity. Reductive
processes are important for hypoxic toxicity; this is demonstrated by the fact that misonidazole, in excess, can
protect against the hypoxic but not aerobic toxicity of RSU 1069. The importance of the interaction of RSU
1069 with DNA, suggested initially by molecular studies, is supported by the fact that cells containing 5-
bromodeoxyuridine (5-BUdR) incorporated into their DNA show greater sensitivity towards the lethal effects
of RSU 1069 both in air and nitrogen, compared to cells not treated with 5-BUdR. Experiments with RSU
1069 and 3-aminobenzamide (3-AB) show the latter compound to potentiate aerobic toxicity, consistent with
monofunctional alkylation by RSU 1069. In contrast, 3-AB has no effect on the hypoxic cytotoxicity of RSU
1069, which would be predicted if RSU 1069 is functioning as a bifunctional agent under these conditions. It
is our contention that in air, RSU 1069 functions as a typical monofunctional alkylating agent, presumably
due to the presence of the aziridine group whereas, in hypoxia, reduction of the nitro group provides an
additional alkylating species, converting the compound into a bifunctional agent.
The compound RSU 1069 (NSC 347503), 1-(2-
nitro-l-imidazolyl)-3-(1-aziridinyl)-2-propanol, has a
similar one-electron reduction potential to that of
misonidazole (Adams, 1984a). However it is both
much more efficient as a radiosensitizer and
considerably more cytotoxic than misonidazole
both in vitro and in vivo (Adams et al., 1984a,b).
Structurally RSU 1069 differs from misonidazole in
that an aziridine replaces the methoxy group in the
NI side-chain of the 2-nitroimidazole. Aziridines
are monofunctional alkylating agents which can
react with cellular macromolecules such as DNA
(see e.g. Ross, 1962) and it has been recently shown
that RSU 1069 and a product(s) of its reduction
can bind to calf thymus DNA and cause single
strand breaks in plasmid DNA (Silver et al., 1985).
The aim of the present work was to characterize
the cytotoxic effect of RSU 1069 at the cellular
level. Results will be discussed with regard to those
obtained in molecular studies (Silver et al., 1985;
Silver & O'Neill, 1986) in order to gain an
understanding of the mechanism of the cytotoxic
effects of RSU 1069 seen under aerobic and
hypoxic conditions.
Materials and methods
Cells
Chinese hamster V79-379A cells were grown in
spinner culture in Eagle's Minimal Essential
Medium (MEM) modified for suspension cultures
and supplemented with 7.5% foetal calf serum (fcs).
Cells were kept in exponential phase at
concentrations between 105 and 106 cellsml-'.
Determination ofcytotoxicity
Generally, cells were exposed to a range of
concentrations of RSU 1069 in air or in N2 for a
fixed time at 37°C. In these experiments 106 cells
were plated into 100ml flat glass bottles and
treated, with 5 ml of drug(s) dissolved in MEM
buffered to pH7.4, when in either mid-exponential
or plateau phase of growth. Where appropriate,
cells were deaerated by flowing N2+5% CO2 at
500mlmin- 1 over the surface of the cell monolayer
throughout the experiment. After treatment
medium was removed, the cells trypsinized, washed
by centrifugation, resuspended, counted, diluted
and plated for colony formation. In other
experiments, cells in suspension were exposed to a
fixed concentration of drug for varying periods of
time as described previously (Stratford & Adams,
1977).
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NAD assay
Cellular NAD levels were determined using a
method similar to that described by Jacobson &
Jacobson (1976). This is an NAD recycling assay,
which depends upon the alcohol dehydrogenase-
catalysed conversion of ethanol to acetaldehyde
followed by reoxidation of the NADH via reaction
between phenazine ethosulphate and MTT (3-
(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide). The reaction leads to a progressive
increase in optical density at 570nm and the initial
rate of increase is dependent upon the initial NAD
concentration. The NAD extraction procedure was
as follows. Following treatment, 2 x 106 cells were
washed with Earle's balanced salt solution, treated
with 0.5M perchloric acid for 15min on ice and
sonicated (MSE Soniprep 150) at amplitude 1 for
20sec (tip size, 9.5mm). The supernatant fractions
were adjusted to pH 7.5 by adding 1.5ml of
1.095moldm-3 KOH in 0.33moldm 3
K2HPO4/KH2PO4 buffer and left on ice for a
further 15min. Insoluble KC104 was then removed
by centrifugation for 10min at 4°C and the
supernatant stored frozen. NAD in the supernatant
was assayed from the rate of change in optical
absorption at 570nm over 1 h using a kinetic
analysis program on a Beckman Du8B UVvis
spectrophotometer.
Glutathione assay
The method of Griffith (1980) was used for the
extraction and determination of intracellular levels
of glutathione as detailed previously by Stratford et
al. (1984).
Compounds
RSU 1069 was synthesized by Drs I. Ahmed and
T.C. Jenkins in this Unit as described previously
(Adams et al., 1984a). All other compounds were
purchased from Sigma (Poole, UK).
Results
The survival of cells taken from confluent cultures
exposed to varying concentrations of RSU 1069 for
3 h in air or N2 is given in Figure 1. Concentrations
of RSU 1069 required for toxicity are much greater
in air than in N2. For example, in air,
300jmoldm-3 RSU 1069 is required to reduce
survival to 10-1, whereas in N2 the concentration
required to give this level of survival is
3,umoldm-3. In comparison the concentrations of
misonidazole required to give a similar level of
survival under comparable conditions are 50 and
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Figure 1 Toxicity of RSU 1069 towards Chinese
hamster V79 cells. (0) nitrogen; (0) air. Cells in
confluent cultures exposed to drug for 3h at 37°C.
5mmdm-3 in air and N2 respectively (Stratford &
Adams 1977; and unpublished data).
An important feature in the toxicity of
misonidazole, particularly under anaerobic
conditions, is the ability of this compound to
deplete cellular thiols (Biaglow, 1983). In order to
assess whether reduction of the total thiol level is
contributing to the cytotoxic action of RSU 1069
we have measured cellular thiol concentrations
before and after exposure to various concentrations
of drug under aerobic and hypoxic conditions
(Table I). At the concentrations tested, many of
which are supra-lethal (cf. Figure 1) there is no
significant reduction of glutathione levels in both
air and nitrogen. However, as total levels of
oxidised and reduced glutathione were measured,
(Griffith, 1980), the possibility that RSU 1069
changes the ratio of reduced and oxidised
glutathione cannot be ruled out. With this proviso,
the data suggest that depletion of intracellular
thiols is not the cause of the high cytotoxic
efficiency of RSU 1069. However, it should be
noted that misonidazole, under similar conditions
of concentration and exposure time, does not
deplete cellular thiols, but under these
circumstances misonidazole is completely non-toxic.
Misonidazole and RSU 1069 are both 2-nitro-
imidazoles with similar electron affinities (Adams et
al., 1976, 1984a). Reduction of the nitro group is a
pre-requisite for the toxicity of misonidazole under
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Table I Total GSH levels in V79 cells
following RSU 1069 for 2h at 37°C
1069 % GSHa
smoldm-3 Air N2
50 93.9+11.6
100 108.6+6.5 94.9+7.4
300 109.1+0.8 100.5+11.2
500 101.6+9.0 83.7+7.5
700 105.6+ 12.3 108.8+ 12.3
900 80.6+4.3 85.6+6.4
1100 91.4+24.2
1400 90.0+6.4
'Each value quoted ±1 s.d. is derived from 3
separate experiments.
hypoxic conditions (Adams et al., 1980) and similar
processes are likely to operate for RSU 1069. One
way of implicating reductive processes in RSU 1069
toxicity would be to inhibit the initial one-electron
reduction step. A method of carrying out this
inhibition under hypoxic conditions would be to
incubate cells with RSU 1069 plus excess
misonidazole. This would be feasible since there is a
large difference in cytotoxic efficiency between RSU
1069 and misonidazole in N2. The compounds have
similar reactivities with reducing agents and hence,
would be expected to compete for reducing
equivalents in proportion to the ratio of their
concentrations. The establishment of the
equilibrium will be
RSU 10692.RSU 1069-
MISO - MISO
fast relative to the lifetimes for the decay of the
radical anions (Clarke et al., 1984). Thus if it is
assumed that the intracellular lifetimes of the one-
electron reduced species of RSU 1069 and
misonidazole (RSU 1069- and MISO'-
respectively) are similar (Wardman, 1985; Silver et
al., 1985), then, with misonidazole in excess,
reduction of RSU 1069 should be substantially
inhibited.
Figure 2 shows results of experiments where cells,
in air or N2 have been exposed to various
concentrations of RSU 1069 plus a 20-fold excess
of misonidazole (95% of reducing equivalents
should go to misonidazole). The maximum
concentrations tested in N2 were 50/pmoldm 3
RSU 1069 and 1 mmdm3 misonidazole, and this
concentration of misonidazole alone was non-toxic
under these experimental conditions. In Figure 2,
the dashed lines are data for RSU 1069 alone
transposed from Figure 1 for comparison. It is
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Figure 2 The effect of misonidazole on the toxicity of
RSU 1069. Cells in confluent cultures exposed to RSU
1069 together with a 20 fold higher concentration of
misonidazole, for 3h at 37°C. (0) nitrogen; (@) air.
The dashed lines, which show the toxicity of RSU
1069 alone, are transposed from Figure 1 for
comparison.
apparent that, under hypoxic conditions,
misonidazole can partially protect cells from the
cytotoxic effect of RSU 1069. However the
protection factor is not equivalent to the 20-fold
difference in concentration and this could be due to
subtle differences in concentration at the site(s)
where reduction takes place. Alternatively, it is
possible that misonidazole could stimulate further
reduction, giving more RSU 1069 - than would be
predicted from their extracellular concentrations.
However, for this to occur, it would depend on the
nature of the nitroreductase system(s) involved in
the one-electron reduction and whether the
concentrations of the nitro compounds are
sufficiently high to saturate these enzymes.
Nevertheless, the results clearly demonstrate the
importance of reduction in the hypoxic toxicity of
RSU 1069. In contrast, in air, the excess
misonidazole has no effect which indicates that the
protective effect of 02 is maximal and reduction is
playing no part in the aerobic toxicity of RSU
1069.
The structural difference between misonidazole
and RSU 1069 is that the latter contains an
aziridine group and it is likely that this moiety
contributes significantly to the much greater
cytotoxic efficiency of RSU 1069. It has been
F
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shown previously (Silver et al., 1985; Silver &
O'Neill, 1986) that RSU 1069 can interact with
DNA via the aziridine and we have carried out
some experiments which suggest that similar
processes may also occur in cells. These
experiments were of two types. Firstly, cells were
labelled for 24h with 10,moldm-3 5-BUdR (5-
bromodeoxyuridine) prior to treatment with RSU
1069. Such cells with 5-BUdR incorporated into
their DNA, have previously been shown to be
much more sensitive to the effect of agents where
DNA is known to be the target e.g. radiation or
alkylating agents (Djordjevic & Zybalski 1960,
Schindler et al., 1966). Secondly, during and after
cytotoxic treatment with RSU 1069 cells have been
exposed to 3-aminobenzamide (3-AB). This
compound can inhibit ADP-ribosyltransferase
(ADPRT), a nuclear enzyme that plays a role in
controlling the ligation step of the excision repair of
damage to DNA including that caused by many
mono-functional alkylating agents (Criessen & Shall
1982). When combined with mono-functional drugs,
3-AB potentiates their cytotoxicity (Nduka et al.,
1980) and this is accompanied by an inhibition of
the NAD depletion consequent upon cytotoxic
treatment (Skidmore et a!., 1979). Figure 3 shows
data for exponentially growing cells given varying
concentrations of RSU 1069 for 1 h in air. The
open symbols represent the survival of control cells
given RSU 1069 alone. Cells labelled with 5-BUdR
are considerably more sensitive to the toxic action
of RSU 1069. Similarly, cells exposed to
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Figure 3 Modification of the aerobic toxicity of RSU
1069 by, (a) incorporation of 5-BUdR into cellular
DNA; (b) holding cells in the presence of
5mmoldm-3 3-AB during and after exposure to RSU
1069. The cells, taken from exponentially growing
cultures, were exposed to various concentrations of
RSU 1069 for 1 h. Open symbols and dashed line,
RSU 1069 alone; closed symbols, cells treated with 5-
B3UdR or 3-AB. All data points are shown except
where s.e. have been calculated from 3 or more
determinations.
5mmdm-3 3-AB during and after treatment with
RSU 1069 are also more sensitive to the aziridinyl
nitroimidazole. Neither the 5-BUdR labelling
procedure, where appropriate precautions were
taken to avoid photo-chemical effects (Ben-Hur &
Elkind, 1972) nor the treatment with 3-AB alone,
results in any cytotoxicity. Intracellular levels of
NAD were also measured following cytotoxic
treatments with RSU 1069 in air, with or without
3-AB. These are shown in Table II. A 1 h treatment
of cells with 2mmdm-3 RSU 1069 in air causes
substantial NAD depletion, which is inhibited by
the concomitant addition of 3-AB. The results
given above suggest that DNA interactions are
important in the toxicity of RSU 1069 in air. These
interactions almost certainly occur via the aziridine
group, since, in similar experiments the toxicity of
misonidazole is not increased (Stratford et al.,
unpublished data).
Table II Effect of 3-aminobenzamide on NAD
depletion caused by RSU 1069
NAD levels
Treatment % control'
2mM RSU 1069 40+9
2mM RSU 1069+3-AB 93+9
3-AB alone 102+3
aMean+s.d. from 3 separate experiments.
Experiments with hypoxic cells have also been
carried out when these cells are labelled with 5-
BUdR and Figure 4 shows results from a
representative experiment for cells treated either
with 50imoldm 3 RSU 1069 or 5mmdm-3
misonidazole for varying periods of time.
Incorporation of 5-BUdR into DNA does not
change the hypoxic toxicity of misonidazole,
whereas, the toxicity of RSU 1069 is increased. The
data in Figure 4 also illustrate the large difference
in the hypoxic cytotoxic efficiency between RSU
1069 and misonidazole.
The results of hypoxic experiments with RSU
1069 and 3-AB are given in Figure 5. Clearly, in N2
3-AB does not potentiate the cytotoxicity of RSU
1069, and in fact it probably has a slight protective
effect. These data, which contrast with the
potentiation of the aerobic cytotoxicity of RSU
1069 by 3-AB suggest the modes of action of RSU
1069 in air and N2 to be quite different.
Comparison of the data for the toxicity of RSU
1069 alone towards exponentially growing cells
(Figure 5) and plateau phase cells (Figure 1) shows
RSU 1069 is more cytotoxic towards cells in the
plateau phase of growth. In V79 cells, this
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Discussion
The aim of the present work was to characterize
the cytotoxicity of RSU 1069 and compare the
results to those obtained in molecular studies. We
have shown the following:
(i) Thiol depletion is unlikely to be important in
the toxicity of RSU 1069.
(ii) In air, indirect evidence suggests RSU 1069
interacts with DNA, presumably via the
aziridine group.
(iii) In N2, reductive processes are involved in the
mechanism of the cytotoxicity.
Previously it has been shown that RSU 1069
binds to calf thymus DNA (Silver et al., 1985) and
1 2 3
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Figure 4 Hypoxic toxicity of 0.05mb
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Figure 5 Hypoxic toxicity of RSU I
exponentially growing V79 cells, 3h a
effect of 5mmdm 3 3-AB during and a
to RSU 1069. All data points are shown
standard errors have been calculated fro
determinations. (0) RSU 1069 alone
1069+5mmdmd3 3-AB.
characteristic of RSU 1069 is shared
of alkylating agents (Smith et al., 1
unpublished data).
4 5 can produce single strand breaks in DNA (Silver et
al., 1985, Edwards et al., 1984). Both these studies
_dm3 RSU stress the importance of the aziridine group in RSU
5-BUdR) and 1069 for these effects. The aerobic survival data we
,labelled with have obtained are consistent with the proposal that
V79 cells with such processes may also occur in cellular DNA.
ir DNA. Additional molecular work shows that a product
of the radiolytic reduction of RSU 1069 binds more
rapidly and to a greater extent to calf thymus DNA
than does unreduced RSU 1069. This extra binding
can be attributed to interaction with DNA via the
reduced nitro moiety, which may serve to
subsequently increase aziridine attack due to
localization at or near its target (Silver et al., 1985).
Results of the cellular experiments in N2 implicate
the importance of reductive processes and the
results with 5-BUdR labelled cells suggest DNA as
a target. However, 3-AB does not potentiate the
hypoxic toxicity of RSU 1069, which contrasts with
its effect under aerobic conditions. The molecular
results imply that under reducing conditions RSU
1069 can become a bifunctional agent and we have
shown previously that 3-AB does not potentiate the
cytotoxicity of bifunctional alkylating agents such
10-4 as melphalan (Walling et al., 1984). Thus, at the
ol dm 3 cellular level, the data obtained with 3-AB suggest that RSU 1069 may have bifunctional character
1069 towards under hypoxic conditions but only act as a
it 37°C. The monofunctional agent in air. Further evidence
Lfter exposure supporting this contention comes from the work of
except where Whitmore and Gulyas (1986), who have used some
m 3 or more DNA repair deficient mutants of CHO cells.
; (0) RSU Among these are UV20 cells, which are exquisitely
sensitive to the cytotoxic action of mitomycin C
and other bifunctional agents. When given RSU
1069 in air the UV20 cells are 5 x more sensitive,
on a drug concentration basis, compared to the
with a range parent CHO cell line. In contrast, in N2 the
982; Walling, sensitivity of the UV20 cells increases 100 fold
(Whitmore & Gulyas, 1986). This implies that RSU
10
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1069 has bifunctional character under hypoxic
conditions.
In conclusion, experiments at the cellular and
molecular level have provided evidence for the
likely mechanism(s) operating in the cytotoxic
actions of RSU 1069 under aerobic and hypoxic
conditions. In air, RSU 1069 appears to act as a
monofunctional alkylating agent, with the potential
to act in a bifunctional manner under hypoxic,
reducing conditions. However, it remains to be
determined whether the reductive processes revealed
here relate to the mechanism(s) of the increased
hypoxic cell radiosensitizing efficiency of this
compound seen both in cells in vitro and solid
tumours in vivo (Adams et al., 1984a,b).
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